Dystrophie musculaire de Duchenne Dystrophie musculaire de Duchenne Dystrophie musculaire de Duchenne

Research

Canadian Research osteoprotegerin (OPG)
By La Force DMD
In Research, Treatments
Posted 10 March 2018

Canadian Research osteoprotegerin (OPG)

Meeting with professor Jérôme Frenette about osteoprotegerin (OPG). We are producing a video series of interviews with Canadian researchers working on DMD. We have met many professors, and our [...]

Portait of Duchenne – repurposing existing drugs for DMD
By La Force DMD
In Research, Treatments
Posted 20 July 2017

Portait of Duchenne – repurposing existing drugs for DMD

Steve J. Winder, PhD Professor of Molecular Cell Biology, Director of Postgraduate Teaching, Director of External Relations, Department of Biomedical Science, The University of Sheffield, United [...]

Portrait of Duchenne – Gene therapy and exon skipping
By La Force DMD
In Research
Posted 8 May 2017

Portrait of Duchenne – Gene therapy and exon skipping

Professor George Dickson   Professor of Molecular Cell Biology, Royal Holloway University of London In the third interview of our series “Portrait of Duchenne”, La Fondation La Force talks [...]

Joining forces to contribute to Canadian research projects
By Marie
In Research
Posted 14 March 2017

Joining forces to contribute to Canadian research projects

Being on the receiving end of a diagnosis of Duchenne Muscular Dystrophy is a very difficult event for parents. Marie-Catherine Du Berger, creator of La Force Foundation knows something about it. [...]

Portrait of Duchenne – Gene replacement therapy
By La Force DMD
In Research
Posted 20 February 2017

Portrait of Duchenne – Gene replacement therapy

  In the first interview of our series “Portrait of Duchenne,” La Force DMD talks with Dr. Jeffrey Chamberlain, a geneticist at the University of Washington, Seattle, about [...]

Utrophin production might be a good option for people with DMD
By Marie
In News, Research, Treatments
Posted 24 October 2016

Utrophin production might be a good option for people with DMD

Utrophin could potentially replace dystrophin. In people with Duchenne muscular dystrophy (DMD), dystrophin does not function properly. Numerous media outlets have recently reported many exciting [...]

Joining Forces To Finance a Promising Research Project on OPG
By La Force DMD
In News, Research
Posted 22 March 2016

Joining Forces To Finance a Promising Research Project on OPG

La Force is proud to announce its participation in the funding of a promising research project on osteoprotegerin, also known as “OPG”. Invited to Boston by the Duchenne Alliance specialists [...]

The approval process for new drugs
By La Force DMD
In Research
Posted 25 February 2016

The approval process for new drugs

When you’re suffering from a fatal (orphan) disease for which there is no cure, such as Duchenne muscular dystrophy, each year, month, day, hour and second that separates you from a potential [...]

CRISPR-cas9 … Genetic engineering offers real hope of advancement
By La Force DMD
In Research
Posted 20 January 2016

CRISPR-cas9 … Genetic engineering offers real hope of advancement

The year 2015 ended with the announcement of great news for the DMD community. Indeed, the scientific community has been voicing much enthusiasm at the discovery of a genetic engineering [...]

1 2 3 4 5 6
page 1 of 6

Articles récents

  • The global day of giving
  • EMBARK, gene therapy for the treatment of DMD
  • Part B of MOMENTUM study of SRP-5051 in patients with DMD
  • World Duchenne Awareness Day 2021
  • ENDEAVOR, gene therapy for DMD

Catégories

  • Fundraising
  • in the Medias
  • News
  • Research
  • Testimonial
  • Treatments

+

Restez informé

    LA Force - Dystrophie musculaire de Duchenne

    La Force dmd - Tous droits réservés - Organisme de bienfaisance enregistré : 817683568RP0001
    La Force dmd La Force dmd
    • S’informer
      • Frequently Asked Questions
    • Make a Donation
    • Agir
      • Quick guige – Management of DMD
      • Take action – What’s your genetic profile?
      • Take action – Subscribe to registries
    • Aller plus loin
      • Go further – How can you access a new treatment?
      • Go further – How do researchers test new treatments?
      • Go further – How are drugs approved for use in Canada?
      • Go further – Who decides to reimburse drug costs?
    • Blog
    • About us
    • Contact-us
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistiques
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
    View preferences
    {title} {title} {title}